United States: The Trans-Pacific Partnership And Its Potential Impact On Exclusivity Periods For Biological Products

After five years of negotiations, the twelve member countries of the Trans-Pacific Partnership (TPP) agreement have reached consensus on its general terms. While the TPP encompasses a broad array of trade-related issues, exclusivity periods for biological products was one of the most controversial issues, and, according to reports, was the "final sticking point" before coming to an actual agreement.1

In the United States, the Biologics Price Competition and Innovation Act (BPCIA) provides a twelve-year period of exclusivity for biologics. Similarly, the European Union, though not involved in the TPP, has a ten-year term of protection for biologics, made up of eight years of data exclusivity and two years of marketing exclusivity.2 During the negotiations, the U.S. trade representative proposed twelve years of exclusivity, mirroring the BPCIA. Australia, however, led opposition to the U.S. proposal and instead fought for a five-year period, which reflects its domestic law.3 Among the TPP member countries, the United States has the longest period of biologics exclusivity, followed by Japan and Canada, both providing eight years. By contrast, the remaining countries, including Chile, Malaysia, New Zealand, and Singapore, provide five or fewer years of data exclusivity, and Brunei, Mexico, Peru, and Vietnam do not grant exclusivity periods for biologics. 4,5,6,7

According to reports and leaked texts, the TPP sets forth two possible market exclusivity schemes for biologics. Under the first option, parties must provide eight years of regulatory data protection for new biologics, beginning on the date of first marketing approval.8 Under the second option, parties must "deliver a comparable outcome in the market" through a five-year period of regulatory data protection and "other measures."9 In effect, the second option appears to formally require only a five-year period of data exclusivity. Statements by Australia's trade minister reinforce that interpretation, as he has said that Australia will not need to change its laws to comply with the TPP biologics provisions.10 The TPP, as currently proposed, mandates minimum protections for biologics, but does not set a maximum term. Therefore, a country might still comply with the TPP even if its exclusivity period is greater than five years.11

Even though the twelve member countries reached a consensus, implementation of the TPP in the United States is far from a certainty. Like other U.S. trade agreements, the TPP is treated as a congressional-executive agreement rather than a treaty.12 As a result, the President and his trade representative may negotiate the agreement, but it has legal force only if it is approved by Congress.13 However, Congress does not vote on the actual TPP; rather it must approve "implementing legislation." Implementing legislation contains provisions that amend existing and create new U.S. federal laws in order to comply with the TPP.14

The 2015 Trade Promotion Authority (TPA) dictates most of the procedural steps for implementation of the TPP. Once the text of the TPP is finalized, the TPA requires the President give Congress 90 days' notice before signing the agreement. Once the President has signed the agreement, he must draft the implementing legislation and submit it to Congress. However, before submitting the legislation, the President must: (1) obtain an ITC assessment of the probable economic effect of the agreement; (2) submit a list of required changes to U.S. law to comply with the agreement; and (3) submit a statement of administrative action proposed to implement the TPP.15 Once the bill is introduced, Congress has 90 days to pass or reject the legislation, during which time the bill must get through the House Ways and Means and Senate Finance Committees, and each house of Congress must vote to approve it.16 If Congress passes the TPP and the President signs it, the TPP takes effect only after the President notifies Congress and all TPP member countries that U.S. law conforms with the TPP.

In light of widespread criticism, it may not be easy to win congressional approval of the TPP.17 Separate from other political issues concerning the effect of the TPP, members of Congress have expressed support for strong intellectual property protections, and specifically a twelve-year period of data exclusivity for biologics.18 Most notably, Senator Orrin Hatch, who chairs the Senate Finance Committee, had demanded strong protections for American pharmaceutical products, including biologics.19 Thus, it is still unclear as to whether biologics in the United States will lose their current twelve years of exclusivity.

Since reaching an agreement on October 5, 2015, the member countries have been drafting the final text. Much of the pharmaceutical industry has expressed disappointment that the TPP would not mandate a twelve-year exclusivity period.20 However, manufacturers of biosimilars have applauded the five-year period as balancing patient access and economic growth.21 The ultimate effect of the TPP internationally is still unclear and will be contingent on the final text of the agreement.

1 James Glenday and Anna Vidot, "Trans-Pacific Partnership: '50/50' chance of trade deal today as negotiators lock horns over medical patent protection," ABC News Australia (Oct., 4, 2015, 11:17 PM), http://www.abc.net.au/news/2015-10-05/pharmaceutical-patent-protection-deal-to-end-tpp-talks/6826956.

2 U.S. Chamber of Commerce, GIPC International IP Index 102 (3d ed. 2015), http://www.theglobalipcenter.com/wp-content/themes/gipc/map-index/assets/pdf/Index_Map_Index_3rdEdition.pdf.

3 Randi Hernandez, "Patent Exclusivity for Biologics: Seven or Twelve Years?", BioPharm International (Jan. 30, 2015), http://www.biopharminternational.com/patent-exclusivity-biologics-seven-or-twelve-years.

4 Brookings Institution, "Health policy 101: How the Trans-Pacific Partnership will impact prescription drugs," Health360 Blog (May 19, 2015, 11:20 AM), http://www.brookings.edu/blogs/health360/posts/2015/05/19-trans-pacific-partnership-prescription-drugs.

5 Alejandro Luna, "Mexico Issues Regulations to Approve Biologic Drugs," Olivares, http://www.olivares.com.mx/En/Knowledge/Articles/PatentArticles/Mexicoissuesregulationstoapprovebiologicdrugs (last visited Oct. 13, 2015).

6> U.S. Chamber of Commerce, GIPC International IP Index 66 (3d ed. 2015), http://www.theglobalipcenter.com/wp-content/themes/gipc/map-index/assets/pdf/Index_Map_Index_3rdEdition.pdf.

7 Michael Mezher, Trade Talks Stumble Over Biologics Data Exclusivity, Regulatory Affairs Professionals Society (Feb. 11, 2015), http://www.raps.org/Regulatory-Focus/News/2015/02/11/21309/Trade-Talks-Stumble-over-Biologics-Data-Exclusivity/.

8 Brett Norman and Sarah Karlin, "Pharma's Next Steps on TPP," Politico (Oct. 12, 2015, 12:02 PM), http://www.politico.com/tipsheets/prescription-pulse/2015/10/pharmas-next-steps-on-tpp-210674.

9 Zachary Brennan, Leaked TPP Chapter on IP Sets Terms of Biologics Data Exclusivity, Regulatory Affairs Professionals Society (Oct. 9, 2015), http://www.raps.org/Regulatory-Focus/News/2015/10/09/23363/Leaked-TPP-Chapter-on-IP-Sets-Terms-of-Biologics-Data-Exclusivity/

10 Transcript, U.S. Trade Representative, Trans-Pacific Partnership Atlanta Ministerial Closing Press Conference (Oct. 5, 2015).

11 Randi Hernandez, "TPP Discussions Conclude; Biologics Now Have Shorter Data Protection Periods," BioPharm International (Oct. 8, 2015), http://www.biopharminternational.com/tpp-discussions-conclude-biologics-now-have-shorter-data-protection-periods.

12 Jane M. Smith et al., Why Certain Trade Agreements Are Approved as Congressional-Executive Agreements Rather Than Treaties (CRS Report No. RL97896) (Washington, DC: Congressional Research Service, 2013).

13 Id.

14 Ian F. Fergusson, Trade Promotion Authority (TPA) and the Role of Congress in Trade Policy (CRS Report No. RL33743) (Washington, DC: Congressional Research Service, 2015) 22.

15 Bipartisan Congressional Trade Authorities and Accountability Act of 2015 19 U.S.C. § 4202

16 Fergusson, 22.

17 Zachary Brennan, Final TPP Agreement Draws Ire from Both Sides over Biologics Exclusivity, Regulatory Affairs Professionals Society (Oct. 5, 2015), http://www.raps.org/Regulatory-Focus/News/2015/10/05/23325/Final-TPP-Agreement-Draws-Ire-from-Both-Sides-over-Biologics-Exclusivity/.

18 Note to Media on Elected Officials Support for 12 Years of Data Protections in TPP, http://phrma.org/note-media-elected-officials-support-12-years-data-protection-tpp.

19 Hatch, Orrin, Hatch Calls for TPA Passage, Seeks Strong Outcomes on Trade Deals in Speech at American Enterprise Institute, Orrin Hatch United States Senator for Utah (Jan. 30, 2015), http://www.hatch.senate.gov/public/index.cfm/2015/1/hatch-calls-for-tpa-passage-seeks-strong-outcomes-on-trade-deals-in-speech-at-american-enterprise-institute.

20 BIO Statement on Data Exclusivity Provisions Within the Trans-Pacific Partnership, Biotechnology Industry Organization (Oct. 4, 2015), https://www.bio.org/media/press-release/bio-statement-data-exclusivity-provisions-within-trans-pacific-partnership.

21 Statement by Chip Davis, President and CEO, GPhA, Regarding the Trans-Pacific Partnership Agreement, Generic Pharmaceutical Association (Oct. 5, 2015), http://www.gphaonline.org/gpha-media/press/statement-by-chip-davis-president-and-ceo-gpha-regarding-the-trans-pacific-partnership-agreement.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
15 Nov 2017, Conference, California, United States

Finnegan is a Gold sponsor of the second annual Digital Media & IP Forum, hosted by World Congress.

15 Nov 2017, Conference, London, UK

Finnegan partner Leythem Wall will consider European claim drafting strategy and will lead the Chemical Workshop during a two-day course, hosted by Management Forum.

15 Nov 2017, Seminar, Amsterdam, Netherlands

Finnegan partner Anthony Tridico will lead Forum Institute for Management’s course comparing patent law in the United States and Europe.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.